Decisional tool to aid portfolio selection decisions into new biotherapeutic modalities

这项研究需要使用决策建模技术来评估与将新的生物制药产品引入公司的投资组合相关的成本、回报和风险，特别是在这个案例中，阿斯利康。大部分工作将涉及将这些建模技术应用于治疗严重和危及生命的疾病的新疗法。该项目的一些主要目的和目标是创建一个工具来评估一些新疗法与阿斯利康现有产品组合的过程经济学。这样做的好处是，它将允许比较和不可避免地确定如何以最具成本效益的方式制造这些新疗法的最佳方法，从而降低患者的治疗成本。它还将允许在过程开发的早期进行这种识别，从而减少典型药物开发的时间尺度，从而使患者能够更快地获得它。从根本上说，总体目标是建立一个成功结合多种标准（包括经济考虑和运营考虑）的工具，以确定和优化阿斯利康药物组合的组成。在这个项目中进行的工作有可能应用于各种生物制药产品组合的情况，因此其他希望开发重要疗法以快速有效地治疗患者的公司可以利用现有的一些工具。这将允许早期识别选择，从而确保治疗更快上市（因此可以使用），并且比以前更具成本效益。

The research entails using decision-making modelling techniques to assess the costs, rewards and risks associated with the introduction of new biopharmaceutical products into a company's portfolio, specifically in this case AstraZeneca. Much of the work will involve applying these modelling techniques to novel therapies that treat serious and life-threatening illnesses. Some of the key aims and objectives of this project are to create a tool to evaluate the process economics of some of these newer therapies against AstraZeneca's current product portfolio. The benefit of this is that it will allow for a comparison and inevitably identification of how best approach the manufacture of these new therapies, in the most cost-effective manner possible, so as to reduce the cost of the therapy to patients. It also will allow for this identification to happen earlier on in the process development, enabling a reduction in the typical drug development timescale, thus allowing it to be available to patients sooner. Fundamentally, the overarching aim is to put in place a tool that successfully incorporates multiple criteria (including economic considerations and operational considerations) to identify and optimise the composition of AstraZeneca's drug portfolio. The work carried out in this project has the potential to be applied to a variety of biopharmaceutical product portfolio situations, whereby other companies that wish to develop vital therapies to rapidly and efficiently treat patients can utilise some of the tools put in place. This will allow for early identification of the options, thus ensuring the therapies are marketed (and so can be used) quicker and are more cost effective than before.